Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This study is a single arm Phase II pilot trial. Patients enrolled on the trial will undergo implantation of high activity iodine-125 seeds into their pituitary adenoma. The tumor response to treatment will be monitored as well as change in visual fields, associated adverse effects, progression free survival and patient reported outcomes.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04212793` - Detection of PitNET Tissue During TSS Using Bevacizumab-800CW	Phase 1
	Terminated	`NCT02396810` - Utilization of iMRI for Transsphenoidal Resection of Pituitary Macroadenomas	N/A

NCT number	NCT01444209
Study type	Interventional
Source	University of Texas Southwestern Medical Center
Contact
Status	Terminated
Phase	Phase 2
Start date	September 30, 2011
Completion date	January 20, 2021

Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms